Clinical trials: Injections
Healthy
Comparing of the PK, PD, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults
A Dual-center , Randomized, double-blinded and Parallel-controlled Study to Assess the Pharmacokinetic, pharmacodynamics, Safety and Immunogenicity of HS-20090 Injection and Xgeva® in Healthy Adults
- Trial name
- NCT05777109
- Testing
- HS-20090, Xgeva®
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Anesthesia, Local
A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution
This is a Phase 3, randomized, placebo-controlled, double masked, parallel design study in healthy subjects performed in the US.
- Trial name
- NCT04513652
- Testing
- AG-920
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- American Genomics, LLC
Inflammation, Cataract
Study of Dexycu in Treating Intraocular Inflammation
This is a phase III, prospective, randomised, double-masked, placebo-controlled, parallel-design, multicenter study of the efficacy, safety and pharmacokinetics of 9% dexamethasone intraocular injection for the treatment of…
- Trial name
- NCT06429306
- Testing
- Dexycu
- Where
- China
- Volunteers
- 285 people
- Sponsor
- Ocumension Therapeutics (Shanghai) Co., Ltd
Postoperative Pain Management in Total Knee Arthroplasty
Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKA
Phase Ⅱ, randomized, double-blind, comparator-controlled study to evaluate the efficacy, safety and pharmacokinetics of single injection adductor canal block with HR18034 for postoperative pain management in total knee…
- Trial name
- NCT06509958
- Testing
- HR18034, Ropivacaine Hydrochloride Injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Osteoarthritis, Knee
Cell-free Stem Cell-derived Extract Formulation for Knee Osteoarthritis
The purpose of this study is to determine the safety and efficacy of intraarticular injection of Cell-free Stem Cell-derived Extract Formulation for treatment of knee osteoarthritis symptoms.
- Trial name
- NCT04971798
- Testing
- Cell-free Stem Cell-derived Extract Formulation (CCM)
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- General Therapeutics
Rapidly Escalating Migraine
Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine
Pilot study to compare the efficacy and safety of two strengths of injections of subcutaneous DFN-11 in subjects with rapidly escalating migraine headaches.
- Trial name
- NCT02571049
- Testing
- DFN-11
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Advanced, Metastatic Breast Cancer
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of Letrozole SIE (injectable) compared to Femara® (oral tablet), both given together with ribociclib, for the first-line treatment of postmenopausal women with…
- Trial name
- SIE-3 (NCT07340658)
- Volunteers
- 300 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Osteoarthritis, Knee
Safety Study of a Long-Acting Injectable Steroid to Treat Knee Osteoarthritis
The main purpose of this study is to understand the pharmacokinetics of EP-104IAR and to determine whether it is safe to use in patients with osteoarthritis (OA) of the knee.
- Trial name
- STEPUP (NCT02609126)
- Testing
- EP-104IAR, Vehicle
- Where
- 3 sites in Canada
- Volunteers
- 32 people
- Sponsor
- Eupraxia Pharmaceuticals Inc.
Relapsed or Refractory Multiple Myeloma
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
The purpose of this study is to characterize the safety of QLS4131 injection and to determine the recommended Phase 2 dose (RP2D) and to further evaluate the efficacy and safety of QLS4131 injection in participants with relapsed…
- Trial name
- NCT06500507
- Testing
- QLS4131 Injection
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Liver Transplantation
Pharmacokinetics of Tacrolimus in Liver Transplantation Patients Treated With Prograf and Modified Release Tacrolimus
Tacrolimus pharmacokinetics study in primary living donor liver transplantation patients with Tacrolimus based immunosuppressive regimens.
- Trial name
- NCT00909571
- Testing
- FK506E (modified release tacrolimus), Prograf (tacrolimus)
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Astellas Pharma Inc
Healthy Volunteers
A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants
The main purpose of this study is to evaluate how the body absorbs and removes LY2605541, insulin lispro, and a mixture of both from the blood. The study has two parts. Participants may enroll in only one part.
- Trial name
- NCT01871493
- Testing
- LY2605541, Insulin Lispro
- Where
- Singapore
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Early-onset Parkinson's Disease
The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease
The goal of this clinical trial is to learn about the safety of NouvNeu001 injection in Early-onset Parkinson's Disease (EOPD) patients. It will also learn about the effects of NouvNeu001 treatment.
- Trial name
- NCT06608355
- Testing
- Human Dopaminergic Progenitor Cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- iRegene Therapeutics Co., Ltd.
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
This is an open-label, multicenter Phase II clinical study aimed at evaluating the tolerability, safety, efficacy, PK profile, and immunogenicity of QLS31905 for Injection combined with QL2107 Injection and XELOX regimen in the…
- Trial name
- NCT06942767
- Testing
- QLS31905 for Injection, QL2107 Injection, Oxaliplatin Injection
- Volunteers
- 100 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS)
A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis
This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of BAT4406F injection in patients with Minimal Change Disease/Focal Segmental Glomerulosclerosis
- Trial name
- NCT07499700
- Testing
- BAT4406F
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Bio-Thera Solutions
Type 1 Diabetes, Diabetes
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.
- Trial name
- QWINT-5 (NCT05463744)
- Testing
- Insulin Efsitora Alfa, Insulin Degludec
- Where
- 83 sites in United States, Argentina and 5 more
- Volunteers
- 692 people
- Sponsor
- Eli Lilly and Company
Metastatic Colorectal Cancer
A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer
This is an open-label, multicenter, dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in combination with FOLFIRI in…
- Trial name
- NCT02453464
- Testing
- Sevacizumab, Irinotecan, 5-FU
- Where
- 3 sites in China
- Volunteers
- 36 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Hemophilia A
Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
This is a multi-center, Phase 1/2/3, single-arm, open-label, single-dose treatment clinical study to evaluate the safety, tolerability and efficacy of BBM-H803 injection in severe Hemophilia A subjects.
- Trial name
- NCT06111638
- Testing
- Single dose intravenous injection of BBM-H803
- Where
- 10 sites in China
- Volunteers
- 55 people
- Sponsor
- Shanghai Xinzhi BioMed Co., Ltd.
Esophageal Cancer
Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer
The Phase Ib stage of this study primarily aims to evaluate the tolerance and safety of TQB6411 Injection in participants with recurrent or metastatic Esophageal cancer who have previously failed treatment with PD-1/PD-L1…
- Trial name
- NCT07367516
- Testing
- TQB6411 Injection
- Where
- 30 sites in China
- Volunteers
- 105 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
COVID-19
Clinical Study of F61 Injection in Healthy Chinese Subjects
Main purpose： To evaluate the safety and tolerability of single-dose ascending intravenous infusion of F61 in healthy subjects. Secondary purpose： To evaluate the pharmacokinetic profile and immunogenicity of F61 administered by…
- Trial name
- NCT05483504
- Testing
- F61 injection
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wuhan Institute of Biological Products Co., Ltd
Chronic Kidney Disease Stage 5 (Dialysis Dependent)
A Randomized, Comparative, Open-label Study of IV Monofer® Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With IV Iron Sucrose in Subjects With CKD-5D
The purpose of this study is to compare the efficacy and safety of intravenous iron isomaltoside 1000 with intravenous iron sucrose in patients suffering from Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D).
- Trial name
- NCT01222884
- Testing
- Monofer, Iron sucrose
- Where
- India
- Volunteers
- 351 people
- Sponsor
- Pharmacosmos A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.